華海藥業(600521.SH)擬推4565萬股的2021年限制性股票激勵計劃
格隆匯 4 月 25日丨華海藥業(600521.SH)發佈2021年限制性股票激勵計劃(草案),擬向激勵對象授予的限制性股票數量為4565萬股,佔草案公吿時公司股本總額的3.138%。其中首次授予4065萬股,佔草案公吿時公司股本總額的2.795%;預留500萬股,佔草案公吿時公司股本總額的0.344%,預留部分佔此次授予權益總額的10.953%。
該激勵計劃首次授予限制性股票的授予價格為10.21元/股。
該激勵計劃擬首次授予的激勵對象總人數為625人,為公司公吿本激勵計劃時在公司(含分子公司,下同)任職的董事、高級管理人員、中層管理人員、核心技術(業務)人員。
該激勵計劃考核年度為2021-2023年三個會計年度,每個會計年度考核一次,首次授予的限制性股票各年度業績考核目標如下表所示:

注:上述“淨利潤”指公司經審計合併報表的歸屬於上市公司股東的扣除非經常性損益後的淨利潤,且以剔除公司實施股權激勵計劃產生的股份支付費用的淨利潤為計算依據,下同。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.